Reuters Photo Credit: Reuters

Sun Pharma to acquire cancer drug from Novartis for $175 mn

23 December, 2016

Sun Pharmaceutical Industries Ltd, India’s biggest drugmaker, plans to acquire skin cancer drug Odomzo from Swiss firm Novartis AG for an upfront payment of $175 million (Rs 1,190 crore).

The company will also make additional milestone payments as part of the proposed deal, it said in a stock-exchange filing on Thursday. It didn’t specify the quantum of these payments.

The deal is subject to anti-trust clearance and other closing conditions, the company said.

Odomzo was approved by the US Food and Drug Administration in July 2015. It is a so-called hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy, Sun Pharma said.

“Odomzo gives us an opportunity to meaningfully expand our already established branded dermatology business and support our expansion into branded oncology with a launched brand,” said Kirti Ganorkar, global head of business development at Sun Pharma.

Sun Pharma, which counts Singapore sovereign wealth fund GIC and state investment firm Temasek as investors, has made several acquisitions and entered new segments over the past months.

In October, Sun Pharma said it would acquire Swiss firm Ocular Technologies from private equity firm Auven Therapeutics to boost its ophthalmic pipeline. Sun Pharma agreed to pay Auven $40 million upfront, plus contingent development milestones and sales milestones as well as tiered royalty on sales of Ocular’s eye disease treatment drug Seciera.

In March, Sun Pharma said it will acquire 14 prescription brands from Swiss firm Novartis in Japan for $293 million in a deal that would help the company to establish a strong footprint in the world’s second-largest pharmaceutical market. 

The drug maker announced its entry into the dermatology segment in June with the launch of its sunscreen product Suncros, as it sought to expand its over-the-counter business.

Like this report? Sign up for our daily newsletter to get our top reports.


Leave Your Comment
Exclusive: Torrent Pharma buying select products of Novartis in India

Exclusive: Torrent Pharma buying select products of Novartis in India

Joseph Rai 5 months ago
Ahmedabad-based drugmaker Torrent Pharmaceuticals Ltd has agreed to acquire some of the products of global healthcare company Novartis in India, VCCircle has learnt. This is...
Sun Pharma acquires 14.58% stake in scPharmaceuticals for $13 mn

Sun Pharma acquires 14.58% stake in scPharmaceuticals for $13 mn

Ranjani Raghavan 8 months ago
Drugmaker Sun Pharmaceutical Industries Ltd has acquired a stake in US-based pharmaceuticals company scPharmaceuticals Inc for $13 million, the firm told stock exchanges on Friday....
Sun Pharma to acquire 14 Novartis brands in Japan for $293M

Sun Pharma to acquire 14 Novartis brands in Japan for $293M

Joseph Rai 1 year ago
Sun Pharmaceutical Industries Ltd will acquire 14 prescription brands from Swiss firm Novartis AG in Japan for $293 million (about Rs 1,950 crore) in a...
No Comments

Sun Pharma to acquire cancer drug from Novartis for $175 mn

Powered by WordPress.com VIP